Arcus Biosciences, Inc.
Customers
1
0 disclosed
Suppliers
0
None disclosed
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Latest period
Dec 31, 2022
10-K filed 2023-02-28
Customers 1
Companies RCUS discloses as major customers, as a share of RCUS revenue. 0 active, 1 lapsed.
| Company | % of RCUS revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| GILD GILEAD SCIENCES, INC. |
96% | $36.5M | FY 2022-12-31 | +2.0pp | Lapsed Last seen 2022-12-31 |
10-K 2023-02-28 |
The following table summarizes the revenue recognized as a result of changes in the deferred revenue balance (in millions): Year Ended December 31, 2022 2021 2020 Revenue recognized from amounts in deferred revenue at the beginning of the period $ 112 $ 202 $ 7 Revenue from the Gilead Collaboration AgreementWe determined that the Amended Gilead Collaboration Agreement (see Note 3, Related party - Gilead Sciences, Inc., for more information) represented a contract modification and at the amendment closing date of December 21, 2021, we allocated the transaction price to the new and remaining performance obligations. | ||||||
Alerts are coming
Get an email when RCUS's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.